Washington, DC: The heads of the International Monetary Fund, World Bank Group, World
Health Organization, and World Trade Organization held high-level
consultations with Gavi and UNICEF on December 17, 2021 aimed at increasing
the use of COVID-19 vaccines and other critical medical countermeasures in
low-income (LIC) and lower middle-income (LMIC) countries and supporting
countries to be better prepared, resourced, and ready to roll out vaccines.
We agreed on the urgency to accelerate vaccinations in LICs, where under 5%
of the population is fully vaccinated, as well as in LMICs, where around
30% of the population is fully vaccinated. We agreed to work with countries
to support and strengthen their national vaccination goals consistent with
the global target to vaccinate 70% of the populations in all countries by
mid-2022. The emergence of the Omicron variant underscores the vital need
for fair and broad access to vaccines as well as testing, sequencing, and
treatments to end the pandemic.
Addressing vaccine inequity, particularly in LICs, requires increasing the
supplies of vaccines to COVAX and AVAT, encouraging LICs and LMICs to
purchase additional vaccine doses, and enhancing country readiness to
deploy vaccines. Furthermore, to facilitate trade flows to support the
manufacturing and distribution of vaccines and other COVID tools, export
restrictions must be rolled back and trade-facilitating measures must be
put in place. Fully funding the ACT-A Accelerator’s Financing Framework
would play an important role in narrowing these gaps and reaching the
global target.
Some LICs and LMICs are facing serious challenges in vaccine deployment.
Constraints related to storage, cold chain capacity, and trained
vaccinators are exacerbated in some cases by doses arriving with short
shelf lives and without adequate lead time and shortages in ancillary
supplies (such as syringes, safety boxes, and dilutants), with challenges
to plan and finance vaccination campaigns in a timely manner. As in
wealthier countries, vaccine hesitancy is also an issue in some LICs and
LMICs.
To address such challenges, we call on governments that have already
achieved high coverage to:
• fulfill their donation pledges as quickly as possible to accelerate
near-term deliveries to COVAX;
• release manufacturers from contracts and options and implement delivery
swaps, so they can prioritize supply to COVAX, AVAT, and low-coverage
countries.
We urge governments that have yet to achieve high vaccination coverage to:
• contract additional doses immediately through AVAT, COVAX, or
bilaterally;
• establish in-country surge capacity to increase the rate of vaccine
utilization as supplies increase; and
• coordinate between health and finance authorities for making increased
use of multilateral development banks’ resources that are readily available
for both vaccine purchase and deployment.
We call for better coordination among vaccine manufacturers, dose donating
countries, COVAX, AVAT, and other partners to improve visibility on vaccine
supply schedules and quality of supply for LICs and LMICs, to support
country-level planning and preparedness for turning vaccines into
vaccinations. Visibility on schedules along with adequate lead times and
shelf lives of vaccines are critical for both equitable distribution as
well as for recipient countries and their partners to prepare for
in-country deployment.
Growing volumes of COVID-19 vaccines are forecast to arrive in LICs and
LMICs in the coming months. Close coordination amongst all stakeholders
will be crucial to help provide countries with the assistance and necessary
resources to increase their capacity to administer those doses. In this
regard, we welcome the recent appointment by UNICEF and WHO, in partnership
with Gavi, of the Global Lead Coordinator for COVID Vaccine Country
Readiness and Delivery, who will play an important key role in
strengthening in-country vaccine deployment.